NCT07209098 - Propensity-Matched Study of Cardiac Contractility Modulation Therapy in Heart Failure | Biotech Hunter

Enrollment

4,200

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2030

Study Completion Date

April 30, 2031

Conditions

Heart Failure and Reduced Ejection FractionNYHA Class III Heart Failure

Interventions

DEVICE

Cardiac Contractility Modulation (CCM)

CCM is a therapy delivered via the Optimizer System, which is implanted in eligible heart failure patients. The device delivers non-excitatory electrical signals to the heart during the absolute refractory period, enhancing the strength of cardiac contractions without increasing myocardial oxygen consumption.